A. Andoh

Publications584
h-index65
Citations17,385
Highly Influential Citations522
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • Y. Fujiyama
  • 523 Publications • 14,319 Citations
  • S. Bamba
  • 194 Publications • 6,241 Citations
  • W. Sandborn
  • 2,046 Publications • 112,656 Citations
  • P. Rutgeerts
  • 1,677 Publications • 107,595 Citations
  • Publications
  • Influence
Increased expression of interleukin 17 in inflammatory bowel disease
TLDR
It is likely that IL-17 expression in IBD may be associated with altered immune and inflammatory responses in the intestinal mucosa and increased in patients with inflammatory bowel disease.
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.
TLDR
A novel microinjection-based local gene-delivery system that is capable of targeting the inflamed intestine and demonstrating a therapeutic potency for IL-22-mediated activation of the innate immune pathway in a mouse model of Th2-mediated colitis that induces disease with characteristics similar to that of IBD ulcerative colitis is developed.
Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts.
TLDR
IL-22 derived from activated T cells acts on SEMFs to elicit expression of proinflammatory cytokines and matrix-degrading molecules indicating proinflammatory/remodeling roles in IBD.
Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis
TLDR
IL-33, derived from colonic SEMFs, may play an important role in the pathophysiology of UC, and is characterized by real-time polymerase chain reaction (PCR) and immunohistochemical methods.
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
TLDR
Curcumin seems to be a promising and safe medication for maintaining remission in patients with quiescent UC, and improved both CAI and EI, thus suppressing the morbidity associated with UC.
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.
TLDR
A biweekly 8 mg/kg infusion of MRA was well tolerated, normalized the acute-phase responses, and suggests a clinical effect in active Crohn's disease.
Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis
TLDR
The gut microbiota of patients with inactive UC tended to be closer to that of healthy individuals, suggesting different roles for the fecal microbiota in the pathophysiology of UC and CD.
Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease
TLDR
Dysbiosis in CD patients was shown by a multi-IBD center study and a logistic model to predict disease activity based on the fecal microbiota composition was developed, which proposed the feasibility of using the feces profile as a predictive marker for disease activity.
Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis
TLDR
The diversity of fecal microbiota in patients with UC was different from that in healthy individuals, and the T‐RFLP patterns were different between the active patients and inactive (remission) patients.
Expression of IL-24, an Activator of the JAK1/STAT3/SOCS3 Cascade, Is Enhanced in Inflammatory Bowel Disease
TLDR
IL-24 derived from colonic SEMFs acts on colonic epithelial cells to elicit JAK1/STAT-3 activation and the expression of SOCS3 and mucins, supporting their suppressive effects on mucosal inflammation in IBD.
...
1
2
3
4
5
...